In the first‐in‐human clinical trial of the KAT6 inhibitor PF‐07248144, researchers performed preliminary biomarker analyses of circulating tumor DNA (ctDNA) mutation profiling at baseline, including ESR1 and PIK3CA/PTEN/AKT1 genes [37]. This evidence concerns the gene AKT1 and neoplasm.